Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 12/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29750258 | 0.85 | MIF (0.47) | MIF | |
| SCHEMBL29644244 | 0.84 | MIF (0.50) | MIF | |
| SCHEMBL6617987 | 0.84 | MIF (0.50) | MIF | |
| SCHEMBL22870022 | 0.84 | MIF (0.50) | MIF | |
| SCHEMBL3983987 | 0.80 | LMNA (0.50) | MIF | |
| SCHEMBL29644228 | 0.78 | MIF (0.39) | MIF | |
| SCHEMBL28897688 | 0.78 | MIF (0.39) | MIF | |
| SCHEMBL6853296 | 0.76 | POLB (0.53) | MIF | |
| SCHEMBL29750358 | 0.76 | MIF (0.43) | MIF | |
| SCHEMBL28897685 | 0.76 | MIF (0.43) | MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035363-A1 | COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12459933-B2 | Compounds and methods of use thereof as antibacterial agents | MERCK SHARP & DOHME LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-20220235041-A1 | COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3997073-A1 | COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | Merck Sharp & Dohme Corp. (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459933-B2 | Compounds and methods of use thereof as antibacterial agents | NDUFB7, MRPL21, SQLE | MIF 1008/4885 |
| US-20220235041-A1 | COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | NDUFB7, MRPL21, SQLE | MIF 1008/4885 |
| US-20260035363-A1 | COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | CBR3, CBR1, NR3C2 | MIF 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.